SHANGHAI PHARMACEUTICALS HOLDING CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.86 CNY | -0.84% |
|
-1.72% | +12.73% |
| 05-27 | Shanghai Pharmaceuticals Holding Co., Ltd Announces Resignation of Chen Fashu as Non-Executive Director | CI |
| 05-27 | Shanghai Pharma Gets Clinical Trial Approval for Antidepressants | MT |
Strengths
- The stock, which is currently worth 2024 to 0.27 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +12.73% | 8.62B | B | ||
| +30.21% | 78.4B | C+ | ||
| +1.68% | 25.12B | C+ | ||
| +2.20% | 8.55B | C | ||
| -30.63% | 6.91B | B- | ||
| +15.63% | 5.34B | B- | ||
| +1.72% | 4.17B | B | ||
| -9.01% | 3.82B | B- | ||
| -8.36% | 3.37B | B+ | ||
| +9.64% | 3.26B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 601607 Stock
- Ratings Shanghai Pharmaceuticals Holding Co., Ltd
